Neurobiology of Dopamine in Schizophrenia
Abstract
This chapter is an update on the dopamine (DA) imbalance in schizophrenia, including the evidence for subcortical hyperstimulation of D2 receptors underlying positive symptoms and cortical hypodopaminergia-mediating cognitive disturbances and negative symptoms. After a brief review of the anatomical neurocircuitry of this transmitter system as a background, we summarize the evidence for dopaminergic alterations deriving from pharmacological, postmortem, and imaging studies. This evidence supports a prominent role for D2 antagonism in the treatment of positive symptoms of schizophrenia and strongly suggests the need for alternative approaches to address the more challenging problem of negative symptoms and cognitive disturbances.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is clear evidence of dysregulated striatal DA function in schizophrenia.
“There is clear evidence of dysregulated striatal DA function in schizophrenia [77]”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [77]
Molecular-imaging evidence indicates dysregulated striatal DA function in schizophrenia.
“Molecular-imaging evidence indicates dysregulated striatal DA function in schizophrenia [77].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [77]
The citation lists haven’t been fetched yet
References 233 · Cited by 365
- Authors
- Guillin, O., Abi‐Dargham, A., & Laruelle, M.
- Affiliations
- New York State Psychiatric Institute (US)
- ORCID
- Abi‐Dargham, Anissa
- Venue
- International Review of Neurobiology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 78
- Pages
- 1-39
- ISSN
- 0074-7742 (ISSN-L)
- OpenAlex
- W1518500152
- Cited by
- 365
- References
- 233
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 6 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 45 · 2016: 17 · 2015: 19 · 2014: 24 · 2013: 32 · 2012: 28
- FWCI
- 110.98
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- International review of neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine, schizophrenia, dopamine D2 receptor, positive symptoms, negative symptoms, cognitive disorders, postmortem studies, neuroimaging
- MeSH terms
- Amphetamine, Animals, Brain, Cognition Disorders, Corpus Striatum, Dopamine, Humans, Receptors, Dopamine, Schizophrenia, Prefrontal Cortex, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
